Role of Cardiorespiratory Fitness and Mitochondrial Energetics in Reduced Walk Speed of

- Older Adults with Diabetes in the Study of Muscle, Mobility and Aging (SOMMA)
- 3 Sofhia V. Ramos¹, Giovanna Distefano¹, Li-Yung Lui^{2,3}, Peggy M. Cawthon^{2,3}, Philip Kramer⁴,
- 4 Ian J. Sipula⁶, Fiona M. Bello⁶, Theresa Mau^{2,3}, Michael J. Jurczak⁶, Anthony J. Molina⁵, Erin E.
- 5 Kershaw⁶, David J. Marcinek⁷, Frederico G.S. Toledo⁶, Anne B. Newman⁶, Russell T. Hepple⁸,
- 6 Stephen B. Kritchevsky⁴, Bret H. Goodpaster¹, Steven R. Cummings^{2,3}, Paul M. Coen¹
- 7 Affiliations:

1

- 8 Translational Research Institute, Advent Health, Orlando, Florida, USA.
- ²San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San
- 10 Francisco, California USA.
- ³Department of Epidemiology and Biostatistics, University of California, San Francisco,
- 12 California, USA.
- ⁴Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North
- 14 Carolina, USA.
- ⁵Department of Medicine, University of California, San Diego, California, USA.
- ⁶Division of Endocrinology and Metabolism, Department of Medicine, School of Medicine,
- 17 University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- ⁷Department of Radiology, University of Washington School of Medicine, Seattle, Washington,
- 19 USA.

21

28

35

39

- ⁸Department of Physical Therapy, University of Florida, Gainesville, Florida, USA.
- 22 Email addresses: Sofhia.ramos@adventhealth.com, Giovanna.distefano@adventhealth.com,
- 23 lily.lui@ucsf.edu, peggy.cawthon@ucsf.edu, pkramer@wakehealth.edu, iansipula@pitt.edu,
- 24 fiona.bello@epfl.ch Theresa.Mau@ucsf.edu, jurczakm@pitt.edu, ajmolina@health.ucsd.edu,
- 25 kershawee@upmc.edu, dmarc@uw.edu, toledofgs7@pitt.edu, anewman@pitt.edu,
- 26 rthepple@phhp.ufl.edu, skritche@wakehealth.edu, bret.goodpaster@adventhealth.com,
- 27 steven.cummings@ucsf.edu
- 29 Correspondence:
- 30 Paul M. Coen, PhD
- 31 AdventHealth, Orlando
- 32 Translational Research Institute
- 33 765-426-9743
- 34 paul.coen@adventhealth.com
- 36 Key Words: Diabetes, Aging, Cardiorespiratory Fitness, Mitochondrial Energetics, Walking
- 37 Speed
- Word count = 3954, Tables = 3, Figures = 1

ABSTRACT Rationale – Cardiorespiratory fitness and mitochondrial energetics are associated with reduced walking speed in older adults. The impact of cardiorespiratory fitness and mitochondrial energetics on walking speed in older adults with diabetes has not been clearly defined. **Objective** – To examine differences in cardiorespiratory fitness and skeletal muscle mitochondrial energetics between older adults with and without diabetes. We also assessed the contribution of cardiorespiratory fitness and skeletal muscle mitochondrial energetics to slower walking speed in older adults with diabetes. Findings – Participants with diabetes had lower cardiorespiratory fitness and mitochondrial energetics when compared to those without diabetes, following adjustments for covariates including BMI, chronic comorbid health conditions, and physical activity. 4-m and 400-m walking speeds were slower in those with diabetes. Mitochondrial oxidative capacity alone or combined with cardiorespiratory fitness mediated ~20-70% of the difference in walk speed between older adults with and without diabetes. Further adjustments of BMI and co-morbidities further explained the group differences in walk speed. **Conclusions** – Skeletal muscle mitochondrial energetics and cardiorespiratory fitness contribute to slower walking speeds in older adults with diabetes. Cardiorespiratory fitness and mitochondrial energetics may be therapeutic targets to maintain or improve mobility in older adults with diabetes.

ARTICLE HIGHLIGHTS
Why did we undertake this study?
To determine if mitochondrial energetics and cardiorespiratory fitness contribute to slower walking speed in older adults with diabetes.
What is the specific question(s) we wanted to answer?
Are mitochondrial energetics and cardiorespiratory fitness in older adults with diabetes lower than those without diabetes? How does mitochondrial energetics and cardiorespiratory fitness impact walking speed in older adults with diabetes?
What did we find?
Mitochondrial energetics and cardiorespiratory fitness were lower in older adults with diabetes compared to those without diabetes, and energetics, and cardiorespiratory fitness, contributed to slower walking speed in those with diabetes.
What are the implications of our findings?
Cardiorespiratory fitness and mitochondrial energetics may be key therapeutic targets to

maintain or improve mobility in older adults with diabetes.

Introduction

The US population is rapidly aging, and in 2022 the percentage of Americans aged 65 and older diagnosed with diabetes remains high at 30% [1]. This represents a healthcare challenge as older adults with diabetes have a greater risk of cardiovascular disease and mobility disability [2, 3]. The contributors to impaired mobility in older individuals with diabetes include the presence of co-morbidity, increased body mass index (BMI) [4], and lower muscle strength and quality [5-7]. However, the relationship between diabetes and loss of mobility remains only partially explained, and other contributors also likely play a role. Our group and others reported that cardiorespiratory fitness and skeletal muscle mitochondrial energetics are linked to reduced walking speed in aging, which is a predictor of mobility disability [8-10]. For example, muscle bioenergetics assessed using ³¹P-MRS was highly correlated with walking speed and partially explained age-related poorer performance in short (6-m) and long (400-m) walking tasks [10]. Several studies have found a close relationship between cardiorespiratory fitness and walking speed in older adults [11], which suggests that the decline in aerobic capacity also contributes to slower walking speed and mobility disability with age.

Muscle biopsies from individuals with diabetes have been shown to have lower oxidative phosphorylation (OXPHOS) capacity compared with muscle from healthy controls [12-14]. However, some studies [15, 16], but not all [12, 13, 17], indicate no differences between patients with diabetes and BMI-matched controls, indicating that obesity *per se* may underlie the lower muscle oxidative capacity. Indeed, other studies in people without diabetes have shown that BMI is strongly related to muscle oxidative capacity [18]. In addition, reports assessing mitochondrial energetics in older adults with diabetes tend to have small sample size and lack adjustment for critical confounding variables including physical activity and adiposity [13, 14, 17], and there are

few reports focusing on older adults with diabetes specifically. Lower fitness is a predictor of insulin resistance and diabetes [19], and prevalence of diabetes is greater in individuals with low fitness [20]. It is unknown whether diabetes associated changes in cardiorespiratory fitness and/or muscle energetics explain slower walking speed seen in people with diabetes, independent of other covariates.

In this analysis, we leveraged data from the Study of Muscle, Mobility and Aging (SOMMA) [21], to investigate the association of diabetes with cardiorespiratory fitness and mitochondrial energetics in a cohort of 879 older adults who were well phenotyped in terms of the free living physical activity behaviors and body composition. We utilized ^{31P}MRS, to measure muscle mitochondrial energetics *in vivo* (ATPmax) and high-resolution respirometry to measure mitochondrial energetics in muscle biopsies, a complementary approach that interrogates mitochondrial OXPHOS capacity at the myocellular level. Here, we tested the hypothesis that diabetes would be associated with lower cardiorespiratory fitness and muscle energetics independent of adiposity, physical activity levels, chronic comorbid health conditions, and oral hypoglycemic medication use. We also tested whether cardiorespiratory fitness and mitochondrial energetics mediate slower walking speed of older adults with diabetes.

RESEARCH DESIGN AND METHODS

Participant Recruitment

The Study of Muscle Mobility and Aging (SOMMA; http://sommaonline.ucsf.edu) is a prospective longitudinal cohort study of older adults and was designed to understand the biological basis of muscle aging [21]. Men and women (70+ yrs. old) were recruited between April 2019 to December 2021. Participants were enrolled at University of Pittsburgh and Wake

Forest University School of Medicine if they were willing and able to complete a skeletal muscle biopsy and undergo Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS). Exclusion criteria included an inability to walk one-quarter of a mile or climb a flight of stairs; had a BMI>40kg/m2; had an active malignancy or dementia; or any medical contraindication to biopsy or MR. Finally, participants must have been able to complete the 400-m walk test; those who appeared as they might not be able to complete the 400-m walk at the in-person screening visit completed a short distance walk (4-m) to ensure their walking speed was \geq 0.6m/s. Presence of diabetes was identified by self-report, use of prescribed hypoglycemic medication, or having an HbA1c \geq 6.5%. WIRB-Copernicus Group (WCG) Institutional Review Board (WCGIRB, study number 20180764) approved the study as the single IRB and all participants provided written informed consent.

Baseline Assessments

Detail on study design and methodology have been published elsewhere [21]. The SOMMA Baseline Visit generally consisted of three days of assessments over several weeks: on "Day 1" the 400-m walk plus most other in-person assessments; "Day 2" cardiopulmonary exercise testing (CPET) and Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) were assessed; "Day 3" muscle biopsy specimen was collected. Age, sex, and race were collected by self-report. The self-reported medical conditions (heart disease, stroke, kidney disease/renal failure, and peripheral vascular disease) were assessed to determine if participants had those conditions or not. Participants were asked to bring all prescription medications they had taken in the 30 days prior to their "Day 1" clinic visit. If a participant forgot to bring one or more medications, clinic staff obtained this information over the telephone or at the return visit. The prescription medication use was reviewed and updated at the additional baseline visit days where

CPET and tissue sampling were done. Body weight, height, and physical function assessments were also measured and accelerometry devices were provided. Most SOMMA participants completed cardiopulmonary exercise testing (CPET), magnetic resonance spectroscopy (MRS) and provided a percutaneous biopsy of the vastus lateralis muscle which was performed under fasted conditions. On the day of the muscle biopsy, participants prescribed oral hypoglycemic medication were asked to take their medications following tissue sampling.

Mobility Assessments

Mobility was assessed by 400m and 4m walking tests. For the 400-m walk test, participants were instructed to walk 10 complete laps around a set course at their usual pace and without overexerting themselves. 4m walking speed was measured in 2 trials and the participant's best time was used to calculate walking speed in m/sec.

Physical Activity Assessments

Two devices were used to assess activity: the thigh-worn activPal that recorded total daily step count and the wrist-worn ActiGraph GT9x. Devices were placed on the participants at the baseline "Day 1" visit with a data collection period of 7 full days. Data was included only if the device was worn over a 24-hour period and had ≥17hour per day wear time. Activity levels collected from ActiGraph were determined by cut points described by Montoye and colleagues [22], and included total daily physical activity time, and time spent in sedentary, light, and moderate to vigorous physical activity (MVPA).

Cardiopulmonary Exercise Testing Assessment

Participants walked for 5 minutes at a preferred walking speed, and progressive symptom-limited exercise protocol ensued with increases in speed (0.5 mph) and incline (2.5%)

in 2-minute increments using a modified Balke protocol or a manual protocol [23, 24].

Cardiorespiratory fitness was determined as VO₂peak (mL/min) which was identified as the

highest 30-second average of VO₂ (mL/min) achieved.

Magnetic Resonance (MR) Imaging and Spectroscopy

³¹Phosphorous-MRS was used to assess *in-vivo* mitochondrial adenosine triphosphate (ATP) generation in the quadriceps muscle during an acute bout of knee isometric extension exercise [21, 24]. A 3 Tesla magnetic resonance magnet (Siemens Medical Systems – Prisma [Pittsburgh] or Skyra [Wake Forest]) with a 2.5" surface RF coil was used for the assessment. All data were analyzed using jMURI v7.0 [25]. Magnetic resonance imaging (MRI) was performed with a 2.5" surface RF coil and used to assess abdominal subcutaneous adipose tissue (ASAT), visceral adipose tissue (VAT), and quadricep muscle fat infiltration (QFI). The entire body was scanned and images were analyzed using AMRA Researcher® (AMARA medical AB, Linköping Sweden) [26].

Muscle Biopsy and Mitochondrial Respiration

Muscle biopsy was completed with a Bergström trocar (5 or 6mm) as previously described [24]. Approximately 10 mg of muscle tissue was allocated for respirometry assays and were immediately submerged in ice cold BIOPS buffer. Fiber bundles of approximately 2-3 mg wet weight were gently teased apart and permeabilized as previously described [24] and weight was measured using an analytical balance (Mettler Toledo, Columbus, OH). Permeabilized fiber bundle (PmFB) oxygen consumption was measured using a high-resolution respirometer (Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria). PmFB were placed into chambers containing MiR05 buffer supplemented with 25μM blebbistatin in the absence of light. Two

protocols were completed in duplicate measuring carbohydrate supported (Protocol 1: 5mM pyruvate and 2mM malate) and fatty acid oxidation (FAO) supported (Protocol 2: 25µM palmitoyl-carnitine and 2mM malate) respiration. For protocol 1, state 3 respiration was stimulated with the addition of 4.2mM ADP (OXPHOS_{CHO}) followed by subsequent additions of 10mM glutamate and 10mM succinate sequentially (maxOXPHOS_{CHO}). Maximal uncoupled respiration was stimulated with consecutive 0.5uM titrations of 2-[2-[4-(trifluoromethoxy)phenyl] hydrazinylidene-propanedinitrile (FCCP) until maximum electron transport system (ETS) capacity was attained (maxETS_{CHO}). For protocol 2, state 3 respiration was stimulated with the addition of 4mM ADP (OXPHOS_{FAO}) followed by subsequent additions of 10mM glutamate and 10mM succinate to further stimulate mitochondrial complexes I and II (maxOXPHOS_{FAO}). PmFB eliciting an oxygen consumption response <15% were not included in the final analysis. Respiratory control ratio (RCR) for protocol 1 (7.11 \pm 2.86) and protocol 2 (3.47 ± 1.74) were assessed for quality control. Respiration was analyzed using DatLab 7.4.0.4. In SOMMA, not all participants completed both protocols due to time constraints. Protocol 1 (carbohydrates) was prioritized over Protocol 2 (fatty acids) when limited technician time was available, which left fewer participants with complete data for Protocol 2.

Statistical Analysis

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

Differences in participant characteristics between older adults with and without diabetes were compared using the T-test for continuous variables (or Kruskal-Wallis non-parametric test for skewed variables) and chi-square test for dichotomized variables. Linear regressions without adjustment were performed to determine differences in cardiorespiratory fitness, and mitochondrial energetics between those with and without diabetes, and additional adjustments for the following confounders: age, race, gender, site/technician, BMI, and chronic conditions

(model 1). Model 1 was further adjusted for steps per day from ActiPal or volume of adipose tissue depots: Abdominal Subcutaneous Adipose Tissue (ASAT), Visceral Adipose Tissue (VAT) and muscle Quadricep Fat Infiltration (QFI). Lastly, to determine the impact of hypoglycemic medication use within the group of older adults with diabetes, multivariate linear regression was performed adjusting for age, race, and site/technician. Those analyses were completed using JMP® Software, Version 16.

Linear regression was also used to determine the association of diabetes with walking speed. We evaluated the potential mediating influence of VO₂peak and/or mitochondrial energetics. We did this by comparing the beta coefficient for the association of diabetes status on walking speed from the 400m and 4m walk. The base model included the confounding variables: gender, age, and race. model 2: base model plus technician and maxOXPHOS_{CHO}, model 3: base model plus technician and maxOXPHOS_{FAO}, model 4: base model plus clinical site and VO₂peak, model 5: base model plus technician, VO₂peak and maxOXPHOS_{CHO}, model 6: base model plus technician, VO₂peak and maxOXPHOS_{FAO}. Fully adjusted models also included the potential mediators/confounders BMI, and chronic conditions. Finally, we compared the percent difference in the beta coefficient between the base model and subsequent models to understand how each adjustment impacted group differences in walking speed. Those analyses were performed using SAS version 9.4 (SAS institute Inc., Cary, NC).

RESULTS

Participant Characteristics

A total of 879 participants (59.2% women) with an average age of 76.5 ± 5.0 years were enrolled in SOMMA [21]. A summary of participants with available data are included in

Supplemental Figure 1. Participant characteristics are summarized in Table 1. 18% of the SOMMA cohort were classified as having diabetes. The proportion of women to men was greater in the group without diabetes (p=0.02). The proportion of White participants compared to non-White was greater in the group without diabetes (p<0.001). Older adults with diabetes had a higher body weight, waist circumference, BMI, and HbA1c (all, p<0.001). Individuals with diabetes tended to have a higher prevalence of heart disease and hypertension, whereas those without diabetes more often had history of cancer diagnosis (p<0.001). Approximately 75% of participants with diabetes reported use of a hypoglycemic agent where 83% used metformin 19% used insulin, and 2% used thiazolidinediones (TZD). Total daily steps, and time in MVPA was significantly lower (p<0.001 for both) and total sedentary time was significantly higher in those with diabetes (p=0.002). In addition, both abdominal subcutaneous adipose tissue (ASAT) and visceral adipose tissue (VAT) volume was significantly higher in older adults with diabetes (p=0.005 for ASAT and p<0.001 for VAT) (Table 1).

Cardiorespiratory Fitness and Muscle Energetics in Diabetes

In the adjusted model (**Table 2**, model 1 + PA), we report that VO_2peak was significantly lower in older adults with diabetes compared to those without (p= 0.004). State 3 (coupled) respiration in the presence of pyruvate + malate (OXPHOS_{CHO}, p= 0.12,) and with the addition of both glutamate and succinate (maxOXPHOS_{CHO}, p= 0.10) was similar between groups. Maximal electron transfer system (ETS) capacity measured by maximal uncoupled respiration with CHO substrates (maxETS_{CHO}, p=0.03) was significantly lower in those with diabetes (**Table 2**). State 3 (coupled) respiration in the presence of palmitoyl carnitine + malate was similar between those with and without diabetes (OXPHOS_{FAO}, p= 0.10). Maximal oxidative

phosphorylation supported by fatty acid substrates (maxOXPHOS $_{FAO}$, p=0.006) remained significantly lower in older adults with diabetes in model 1 + PA. Sensitivity analyses completed in those with data for both Protocol 1 and Protocol 2 had similar results (data not shown) to ensure that differences between protocols were not due to differences in sample size.

Adjustment for levels of QFI, ASAT and VAT did not impact group differences in mitochondrial energetics and VO₂peak measurements with an exception for OXPHOS_{CHO} (**Table 2**). Adjustment for VAT tended to explain some variance in OXPHOS_{CHO} between those with and without diabetes (p=0.06, **Table 2**). Within the diabetes group only, ATPmax was lower in older adults taking any hypoglycemic medication (p=0.05) or metformin alone (p=0.01, **Supplemental table 1**). These findings make it difficult to distinguish the impact of medications versus diabetes on ATPmax and therefore, further analysis of mitochondrial energetics focused on respiration measurements. VO₂peak and mitochondrial energetics assessed by respiration were similar with the use of all hypoglycemic agents and metformin (**Supplemental Table 1**).

VO_2 peak and Mitochondrial Energetics Mediate the Relationship between Diabetes and Walking Speed

Lastly, 400-m and 4-m walking speeds were significantly lower in those with diabetes compared to those without diabetes following adjustments for gender, age, and race (base model, **Table 3**). To assess whether VO₂peak and mitochondrial energetics mediated the relationship between diabetes and walk speed, we compared the β coefficient for mean 400-m and 4-m walking speed from the base linear regression model with the β coefficient of models that included VO₂peak and/or mitochondrial energetics variables. Additional individual adjustments for maxOXPHOS_{CHO} (400-m, p=0.02, model 2), maxOXPHOS_{FAO} (400-m, p=0.02; model 3) and VO₂peak (400-m p=0.01; model 4) resulted in no significant change in group differences in

400-m walking speed between those with and those without diabetes (**Table 3**). Alternatively, for 4-m walking speed, further adjustments for maxOXPHOS_{CHO} (4-m, p=0.12; model 2) and maxOXPHOS_{FAO} (4-m, p=0.51, model 3) significantly mediated differences between groups, whereas VO₂peak (4-m, p=0.04, model 4) did not. Examining the impact of combinations of VO₂peak and mitochondrial energetics revealed that VO₂peak with maxOXPHOS_{CHO} (400-m p=0.07, 4-m p=0.27; model 5) or maxOXPHOS_{FAO} (400-m, p=0.20, 4-m, p=0.99) mediated differences between those with and without diabetes. Full adjustments including potential confounders/mediators BMI and chronic conditions explained the remaining variance in walking speed between groups. (**Table 3**). Comparing the β coefficient for mean 400-m and 4-m walking speed from the base linear regression model with the β coefficient of models that included both VO₂peak and mitochondrial energetics variables revealed that VO₂peak and mitochondrial energetics explained an additional ~46-100% of the variance in 400-m and 4-m walking speed between groups (**Figure 1**).

DISCUSSION

In this study of 879 well-phenotyped older adults we found that the 159 participants with diabetes had slower 4- and 400-m walk speed. We report for the first time that the association of diabetes status with slow walking speed was mediated by VO₂peak and skeletal muscle mitochondrial energetics. We also examined differences in cardiovascular fitness and mitochondrial energetics between those with and without diabetes while controlling for physical activity and adiposity. Interestingly, accounting for these potential confounders did not explain differences in VO₂peak and mitochondrial respiration between those with and without diabetes, suggesting other factors may impact cardiorespiratory fitness and energetics in those with diabetes. We also found that older adults taking hypoglycemic medications (insulin, TZDs,

and/or metformin) or metformin alone had significantly lower ATPmax (but not respirometry measures of mitochondrial energetics) compared to older adults with diabetes but not taking medications, providing evidence that aligns with reports in the literature that metformin can impair mitochondrial energetics.

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

The well-phenotyped SOMMA cohort provided an opportunity to assess the impact of diabetes status on VO₂peak and mitochondrial energetics in older adults while controlling for objectively measured indices of physical activity, adiposity, and chronic conditions in addition to demographic variables. Many of the previous studies reporting lower muscle oxidative capacity measured in permeabilized fiber bundles from patients with diabetes have not rigorously assessed and controlled for the participants' physical activity [12-14, 17]. This is important as physical activity interventions (such as walking) can improve mitochondrial energetics in type 2 diabetes [27] and during weight loss in obesity [28], and in older adults [29]. Here, we report that lower levels of objectively assessed physical activity partially explains lower respiration in older adults with diabetes. Interestingly, comparing our respirometry protocols with distinct substrate combinations, we found that CI+II FAO supported maxOXPHOS respiration remains lower in the diabetes group, while CI+II CHO only supported maxOXPHOS did not differ following adjustments for physical activity. This suggests that CHO supported coupled respiration may be more sensitive to levels of physical activity compared to FAO supported respiration. This is also in line with evidence indicating reduced rates of lipid oxidation in skeletal muscle from individuals with diabetes, potentially due to mitochondrial overload and incomplete fatty acid oxidation [30].

The influence of adiposity on mitochondrial energetics has been considered in prior studies of diabetes, typically by matching control subjects for BMI [14]. Some studies [15, 16],

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

but not all [12, 13, 17], indicate no differences between patients with diabetes and BMI-matched controls, suggesting that obesity *per se* may underlie the lower muscle oxidative capacity. Here, we examined the influence that BMI and specific adipose depots (ASAT, VAT, and QFI) had on muscle mitochondrial energetics in diabetes. However, regardless of whether adiposity was adjusted for BMI alone or combined with individually objectively measured adipose depots, mitochondrial respiration generally remained significantly lower in those with diabetes. Taken together, these findings indicate that adiposity and physical activity largely (there were some exceptions) do not entirely explain lower mitochondrial energetics in older adults with diabetes.

Metformin is one of the most commonly prescribed medications for diabetes, and although its mechanism of action remains highly debated, there is evidence of an inhibitory effect on complex I of the electron transport chain [31]. Both pre-clinical and clinical studies report maladaptation of mitochondrial function following metformin treatment, increased muscle atrophy and reduced exercise capacity, specifically in older adults [31, 32]. Conversely, others have reported that metformin can improve mitochondrial function via effects on mitophagy, autophagy or AMPK activation [33]. Our understanding of how metformin impacts skeletal muscle mitochondrial function of older adults with diabetes is limited. Here, we reveal lower ATPmax in older adults with diabetes taking hypoglycemic medication or metformin alone, compared to older adults with diabetes not taking medications. Interestingly, we did not observe an association of metformin with diabetes status in the respiration assays, suggesting different sensitivities to metformin based on whether mitochondrial energetics are assessed in vivo (ATPmax) compared to permeabilized fiber bundle preparations ex vivo. However, an important caveat is that participants were asked to withhold medication prior to the muscle biopsy and respirometry assays but not on the day of ^{31P}MRS assessments. In addition, others have reported

no effect on mitochondrial respiration after a two-week metformin treatment compared to control [34], or in long term diabetes patients [35]. Given that metformin is water soluble, it is also plausible that the inhibitory effect of metformin is lost when the muscle fiber bundles are washed in preparation for the respirometry assay. Further work is needed to decipher the impact metformin has on skeletal muscle mitochondrial energetics in older adults with diabetes.

Zhao and colleagues reported that adults with diabetes were 31-34% less likely to participate in physical activity, which in turn may contribute to lower VO₂peak [36]. In line with these reports, SOMMA participants with diabetes were significantly less active and significantly more sedentary. Our results show that additional adjustments for physical activity did not resolve differences in VO₂peak between groups, suggesting that lower VO₂peak in older adults with diabetes is independent of physical activity in this cohort. In addition, we report that independent of adiposity measured by BMI or combined BMI with ASAT, VAT and QFI, VO₂peak remained significantly lower in those with diabetes compared to those without. Taken together, our work suggests that physical activity and adiposity may not be implicated in lower cardiorespiratory fitness in older adults with diabetes and that other factors including perhaps genetics and heritability are more important determinants to low cardiorespiratory fitness in diabetes.

Previous work from our laboratory and others revealed a significant relationship between walking speed with both VO₂peak and mitochondrial energetics in older adults [9, 37, 38]. Here, we explored the contribution of both mitochondrial energetics and cardiorespiratory fitness to mobility in older adults with diabetes. We report that mitochondria respiration, both independently (~40-70%) and combined with VO₂peak (~55-100%), mediated the variance in 4-m walking speed in those with diabetes. Differences between groups are further explained by additional adjustments for potential confounders/mediators BMI, and comorbidities. Reports

indicate that muscle mass is lost at an accelerated rate in older adults with diabetes [7], contributing to reductions in muscle strength and quality [6], and ultimately reducing physical function and mobility [5, 39]. We extended these findings by highlighting how mitochondrial energetics may independently and combined with cardiorespiratory fitness also contribute to lower walk speed in older adults with diabetes. This finding is of particular interest because slower walking speed is an important indicator of health and has been shown to associate with survival in older adults [38]. This data raises the possibility that cardiorespiratory physiology and mitochondrial energetics could be targeted to prevent mobility loss in older adults with diabetes.

There are some limitations to the study that should be considered. First, the duration of diabetes status of SOMMA participants and the length of time that participants have been taking oral hypoglycemic agents were not recorded. We acknowledge that our study participants were predominantly (85.6%) non-Hispanic White which limits our ability to generalize to other race/ethnic groups where mobility disability is more prevalent [40]. In addition, all participants recruited were able to complete 4-m walk test at a gait speed of greater than or equal to 0.6m/s and which may be faster than those with more advanced diabetes who are unable to complete mobility related tasks [2]. Nevertheless, we observe differences in physiological and functional aspects of skeletal muscle signifying the impact that diabetes has in the SOMMA cohort. The strengths of our study are the large sample size of participants and rigorous assessment of objectively measured physical activity, fitness and body composition, and collection of muscle biopsies for fresh tissue assays.

In summary, our findings highlight that mitochondrial energetics independently and combined with cardiorespiratory fitness contribute to the difference in 400-m and 4-m walk

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

speed in older adults with diabetes. Additionally, future work should aim to decipher the impact of diabetes medication on mitochondrial function as this remains to be a gap in the literature. **ACKNOWLEDGEMENTS Personal thanks -** We gratefully acknowledge and thank all participants who participated in this study at the University of Pittsburgh and Wake Forest University. We acknowledge the dedicated staff and investigators at both clinical sites as well as at the San Francisco Coordinating Center. Collection and analyses of ³¹Phosphorous Magnetic Spectroscopy data would not have been possible without the support from Eric Shankland. Funding and Assistance – The National Institute on Aging (NIA) funded the Study of Muscle, Mobility, and Aging (SOMMA; R01AG059416). In part, infrastructure support for SOMMA was funded by the NIA Claude D. Pepper Older American Independence Centers at the University of Pittsburgh (Pitt) and Wake Forest University School of Medicine (Wake), P30AG024827 and P30AG021332 respectively. More SOMMA infrastructure support from the Clinical and Translational Science Institutes is funded by the National Center for Advancing Translational Science at both Wake (UL1TR001420). PMCo is supported by R01AG060153 and R01AG060542. GD was supported by the American Diabetes Association (1-19-PDF-006) during data collection and analysis. Conflict of Interest – SRC and PMCa are consultants to Bioage Labs. PMCa is a consultant to and owns stock in MyoCorps. All other authors report no conflict of interest. Author Contributions and Guarantor Statement – SVR and LYL completed statistical analysis with final review from the statistical team at the coordinating center. SVR and PMCo conceived the idea and co-wrote the manuscript. LYL, GD, SM, PMCo and PK completed

experiments or completed quality control, validation, and interpretation of data. LYL, GD, PMCa, PK, TM, SM, MJJ, AJM, EEK, DJM, FGST, SRC, ABN, RTH, SBK, BHG edited the manuscript. SRC, PMCa, ABN, SBK, RTH, and BHG enabled the study with either funding acquisition, project administration, and/or conceptualization to the study.

Prior Presentations – Data from this manuscript has been presented at the following meetings: American Diabetes Association 83rd Scientific Sessions May 30th – June 6th 2022, and the American College of Sports Medicine Annual Meeting and World Congress, May 30th – June 2nd, 2023.

REFERENCES

437

- 438 1. Centers for Disease Control and Prevention. National Diabetes Statistics Report website.
- 439 2. Gregg, E.W., et al., *Diabetes and physical disability among older U.S. adults.* Diabetes Care, 2000. **44**0 **23**(9): p. 1272-7.
- Ryerson, B., et al., *Excess physical limitations among adults with diabetes in the U.S. population,* 1997-1999. Diabetes Care, 2003. **26**(1): p. 206-10.
- 443 4. Gregg, E.W., et al., *Diabetes and incidence of functional disability in older women.* Diabetes Care, 2002. **25**(1): p. 61-7.
- Volpato, S., et al., *Role of muscle mass and muscle quality in the association between diabetes and gait speed.* Diabetes Care, 2012. **35**(8): p. 1672-9.
- 447 6. Park, S.W., et al., Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes, 2006. **55**(6): p. 1813-8.
- 7. Park, S.W., et al., *Excessive loss of skeletal muscle mass in older adults with type 2 diabetes.*Diabetes Care, 2009. **32**(11): p. 1993-7.
- 451 8. Coen, P.M., et al., *Skeletal muscle mitochondrial energetics are associated with maximal aerobic* 452 capacity and walking speed in older adults. J Gerontol A Biol Sci Med Sci, 2013. **68**(4): p. 447-55.
- Gonzalez-Freire, M., et al., Skeletal muscle ex vivo mitochondrial respiration parallels decline in vivo oxidative capacity, cardiorespiratory fitness, and muscle strength: The Baltimore
 Longitudinal Study of Aging. Aging Cell, 2018. 17(2).
- 456 10. Choi, S., et al., 31P Magnetic Resonance Spectroscopy Assessment of Muscle Bioenergetics as a 457 Predictor of Gait Speed in the Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med 458 Sci, 2016. **71**(12): p. 1638-1645.
- Newman, A.B., et al., Walking performance and cardiovascular response: associations with age
 and morbidity--the Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med Sci,
 2003. 58(8): p. 715-20.
- 462 12. Phielix, E., et al., Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo 463 mitochondrial dysfunction in muscle of male type 2 diabetic patients. Diabetes, 2008. **57**(11): p. 464 2943-9.
- 465 13. Kelley, D.E., et al., *Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes.*466 Diabetes, 2002. **51**(10): p. 2944-50.
- 467 14. Mogensen, M., et al., *Mitochondrial respiration is decreased in skeletal muscle of patients with* 468 type 2 diabetes. Diabetes, 2007. **56**(6): p. 1592-9.
- 469 15. Boushel, R., et al., *Patients with type 2 diabetes have normal mitochondrial function in skeletal* 470 *muscle.* Diabetologia, 2007. **50**(4): p. 790-6.
- 471 16. Larsen, S., et al., Are substrate use during exercise and mitochondrial respiratory capacity decreased in arm and leg muscle in type 2 diabetes? Diabetologia, 2009. **52**(7): p. 1400-8.
- 473 17. Schrauwen-Hinderling, V.B., et al., Impaired in vivo mitochondrial function but similar
 474 intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control
 475 subjects. Diabetologia, 2007. **50**(1): p. 113-20.
- Distefano, G., et al., *Physical activity unveils the relationship between mitochondrial energetics,*muscle quality, and physical function in older adults. J Cachexia Sarcopenia Muscle, 2018. **9**(2): p.
 279-294.
- 479 19. Leite, S.A., et al., Low cardiorespiratory fitness in people at risk for type 2 diabetes: early marker for insulin resistance. Diabetol Metab Syndr, 2009. **1**(1): p. 8.
- 481 20. Lee, D.C., et al., Associations of cardiorespiratory fitness and obesity with risks of impaired fasting glucose and type 2 diabetes in men. Diabetes Care, 2009. **32**(2): p. 257-62.

- Cummings, S.R., et al., *The Study of Muscle, Mobility and Aging (SOMMA). A Unique Cohort*Study about the Cellular Biology of Aging and Age-related Loss of Mobility. J Gerontol A Biol Sci
 Med Sci, 2023.
- 486 22. Montoye, A.H.K., et al., *Development of cut-points for determining activity intensity from a wrist-worn ActiGraph accelerometer in free-living adults.* J Sports Sci, 2020. **38**(22): p. 2569-2578.
- Balady, G.J., et al., Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation, 2010. **122**(2): p. 191-225.
- 490 24. Mau, T., et al., Mitochondrial energetics in skeletal muscle are associated with leg power and
 491 cardiorespiratory fitness in the Study of Muscle, Mobility, and Aging (SOMMA). J Gerontol A Biol
 492 Sci Med Sci, 2022.
- 493 25. Naressi, A., et al., Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med, 2001. **31**(4): p. 269-86.
- 496 26. Borga, M., et al., *Reproducibility and repeatability of MRI-based body composition analysis.*497 Magn Reson Med, 2020. **84**(6): p. 3146-3156.
- Toledo, F.G., et al., Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. Diabetes, 2007. **56**(8): p. 2142-7.
- 500 28. Coen, P.M., et al., Exercise and Weight Loss Improve Muscle Mitochondrial Respiration, Lipid
 501 Partitioning, and Insulin Sensitivity After Gastric Bypass Surgery. Diabetes, 2015. **64**(11): p. 3737502 50.
- Pruchnic, R., et al., *Exercise training increases intramyocellular lipid and oxidative capacity in older adults.* Am J Physiol Endocrinol Metab, 2004. **287**(5): p. E857-62.
- Kelley, D.E. and J.A. Simoneau, *Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus*. J Clin Invest, 1994. **94**(6): p. 2349-56.
- Wessels, B., et al., Metformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dose-dependent manner. PLoS One, 2014. **9**(6): p. e100525.
- 509 32. Konopka, A.R., et al., *Metformin inhibits mitochondrial adaptations to aerobic exercise training* in older adults. Aging Cell, 2019. **18**(1): p. e12880.
- de Maranon, A.M., et al., *Metformin modulates mitochondrial function and mitophagy in* peripheral blood mononuclear cells from type 2 diabetic patients. Redox Biol, 2022. **53**: p. 102342.
- 514 34. McKenzie, A.I., et al., Short-term exposure to a clinical dose of metformin increases skeletal 515 muscle mitochondrial H(2)O(2) emission and production in healthy, older adults: A randomized 516 controlled trial. Exp Gerontol, 2022. **163**: p. 111804.
- 517 35. Larsen, S., et al., *Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration.* Diabetologia, 2012. **55**(2): p. 443-9.
- 519 36. Zhao, G., et al., *Physical activity in U.S. older adults with diabetes mellitus: prevalence and*520 correlates of meeting physical activity recommendations. J Am Geriatr Soc, 2011. **59**(1): p. 132-7.
- 521 37. Coen, P.M., et al., Reduced skeletal muscle oxidative capacity and elevated ceramide but not diacylglycerol content in severe obesity. Obesity (Silver Spring), 2013. **21**(11): p. 2362-71.
- 523 38. Studenski, S., et al., Gait speed and survival in older adults. JAMA, 2011. 305(1): p. 50-8.
- 524 39. De Rekeneire, N., et al., Diabetes is associated with subclinical functional limitation in
- 525 nondisabled older individuals: the Health, Aging, and Body Composition study. Diabetes Care, 526 2003. **26**(12): p. 3257-63.
- 527 40. Okoro, C.A., et al., *Prevalence of Disabilities and Health Care Access by Disability Status and Type*528 Among Adults United States, 2016. MMWR Morb Mortal Wkly Rep, 2018. **67**(32): p. 882-887.

 Table 1: Participant Characteristics

N 717 159 Age (year) 76.47 ± 5.05 75.79 ± 4.84 Female 61(438) 51(81) Race (white) 88(631) 70(111) Hispanic ethnicity 1(7) 1(2) Weight (kg) 74.74 ± 14.75 82.41 ± 15.58 Height (m) 1.66 ± 0.10 1.67 ± 0.10 Waist circumference (cm) 92.69 ± 12.98 100.90 ± 12.57 BMI (kg/m²) 27.17 ± 4.44 29.55 ± 4.63 HbA1c (%) 5.51 ± 0.31 6.73 ± 0.89 Systolic blood pressure (mmHg) 129.71 ± 15.80 133.72 ± 16.08 Co-morbidities 13(93) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) M	p-value
Female 61(438) 51(81) Race (white) 88(631) 70(111) Hispanic ethnicity 1(7) 1(2) Weight (kg) 74.74 ± 14.75 82.41 ± 15.58 Height (m) 1.66 ± 0.10 1.67 ± 0.10 Waist circumference (cm) 92.69 ± 12.98 100.90 ± 12.57 BMI (kg/m²) 27.17 ± 4.44 29.55 ± 4.63 HbA1c (%) 5.51 ± 0.31 6.73 ± 0.89 Systolic blood pressure (mmHg) 129.71 ± 15.80 133.72 ± 16.08 Co-morbidities Lung disease 13(93) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472)<	
Race (white) 88(631) 70(111) Hispanic ethnicity 1(7) 1(2) Weight (kg) 74.74 ± 14.75 82.41 ± 15.58 Height (m) 1.66 ± 0.10 1.67 ± 0.10 Waist circumference (cm) 92.69 ± 12.98 100.90 ± 12.57 BMI (kg/m²) 27.17 ± 4.44 29.55 ± 4.63 HbA1c (%) 5.51 ± 0.31 6.73 ± 0.89 Systolic blood pressure (mmHg) 129.71 ± 15.80 133.72 ± 16.08 Co-morbidities Lung disease 13(93) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications	0.12
Hispanic ethnicity Weight (kg) 74.74 ± 14.75 82.41 ± 15.58 Height (m) 1.66 ± 0.10 1.67 ± 0.10 Waist circumference (cm) 92.69 ± 12.98 100.90 ± 12.57 BMI (kg/m²) 27.17 ± 4.44 29.55 ± 4.63 HbA1c (%) 5.51 ± 0.31 6.73 ± 0.89 Systolic blood pressure (mmHg) 129.71 ± 15.80 133.72 ± 16.08 Co-morbidities Lung disease 13(93) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) Insulin 19(23)	0.02
Weight (kg) 74.74 ± 14.75 82.41 ± 15.58 Height (m) 1.66 ± 0.10 1.67 ± 0.10 Waist circumference (cm) 92.69 ± 12.98 100.90 ± 12.57 BMI (kg/m²) 27.17 ± 4.44 29.55 ± 4.63 HbA1c (%) 5.51 ± 0.31 6.73 ± 0.89 Systolic blood pressure (mmHg) 129.71 ± 15.80 133.72 ± 16.08 Co-morbidities Lung disease 13(93) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications 75(118) • Insulin 75(118)	< 0.001
Height (m) 1.66 ± 0.10 1.67 ± 0.10 Waist circumference (cm) 92.69 ± 12.98 100.90 ± 12.57 BMI (kg/m²) 27.17 ± 4.44 29.55 ± 4.63 HbA1c (%) 5.51 ± 0.31 6.73 ± 0.89 Systolic blood pressure (mmHg) 129.71 ± 15.80 133.72 ± 16.08 Co-morbidities Lung disease 13(93) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) • Insulin 19(23)	0.76
Waist circumference (cm) 92.69 ± 12.98 100.90 ± 12.57 BMI (kg/m²) 27.17 ± 4.44 29.55 ± 4.63 HbA1c (%) 5.51 ± 0.31 6.73 ± 0.89 Systolic blood pressure (mmHg) 129.71 ± 15.80 133.72 ± 16.08 Co-morbidities Lung disease 13(93) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) • Insulin 19(23)	< 0.001
BMI (kg/m²) BMI (kg/m²) BMI (kg/m²) Systolic blood pressure (mmHg) Co-morbidities Lung disease Lung disease 13(93) Stroke 13(16) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) Hypertension Cancer 43(308) 44(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) • Insulin 19(23)	0.16
HbA1c (%) 5.51 ± 0.31 6.73 ± 0.89 Systolic blood pressure (mmHg) 129.71 ± 15.80 133.72 ± 16.08 Co-morbidities Lung disease Lung disease 13(93) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) • Insulin 75(118)	< 0.001
Systolic blood pressure (mmHg) 129.71 ± 15.80 133.72 ± 16.08 Co-morbidities Lung disease 13(93) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications - 75(118) • Insulin 75(118)	< 0.001
Co-morbidities Lung disease 13(93) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) • Insulin 19(23)	< 0.001
Lung disease 13(93) 14(22) Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) • Insulin 19(23)	0.004
Arthritis 57(409) 52 (83) Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) • Insulin 19(23)	
Stroke 2(16) 3(5) Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications 75(118) • Insulin 19(23)	0.77
Heart disease 6(42) 11(18) Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) ■ Insulin 19(23)	0.25
Cancer 43(308) 24(38) Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications 75(118) • Insulin 19(23)	0.51
Hypertension 26(187) 37(59) Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications 75(118) ♠ Insulin 19(23)	0.02
Kidney disease/renal failure 3(24) 6(9) Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications 75(118) • Insulin 19(23)	< 0.001
Peripheral vascular disease 1(4) 1(2) Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications 75(118) • Insulin 19(23)	0.006
Hypothyroidism 19(133) 17(27) Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications 75(118) ◆ Insulin 19(23)	0.19
Glaucoma 9(65) 11(18) Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) • Insulin 19(23)	0.37
Macular degeneration 9(61) 5(8) Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) ● Insulin 19(23)	0.64
Cataracts 66(472) 62(99) Hypoglycemic Medications All 75(118) • Insulin 19(23)	0.39
Hypoglycemic Medications All 75(118) • Insulin 19(23)	0.12
All 75(118) • Insulin 19(23)	0.37
• Insulin 19(23)	
` ^	
• Metformin 84(99)	
• Thiazolidinediones 3(3)	
Physical Activity	
Total daily steps $7066.68 \pm 3233.95 \hspace{0.2in} 5848.70 \pm 2791.12$	< 0.001
Total sedentary time (min) 610.10 ± 112.28 659.40 ± 108.65	< 0.001

Time in light physical activity (min)	98.20 ± 26.54	92.84 ± 29.16	0.027
Time in moderate to vigorous physical activity (min)	192.95 ± 86.40	155.66 ± 76.74	<0.001
Body Adiposity			
Abdominal adipose tissue volume (L)	7.50 ± 3.14	8.30 ± 3.31	0.005
Visceral adipose tissue volume (L)	3.96 ± 2.21	5.36 ± 2.31	< 0.001
Quadricep fat infiltration (%)	0.07 ± 0.02	0.07 ± 0.02	0.002

Data presented as means \pm standard deviation or % (N). Hypoglycemic medications is calculated only for those taking medications. Significance accepted at **p<0.05** and indicated with bold font.




Figure 1. Percent reduction in the association between diabetes and 400-m and 4-m walking speed after adjusting for both individual and combined carbohydrate and fatty acid supported respiration, and cardiorespiratory fitness. Bars depict the reduction in β coefficient from linear regression models (models 2-6 compared to the base model: $[1-(\beta \text{ adjusted/β base adjusted})]$. Base model: age, gender, and race, model 2: base model + maxOXPHOS_{CHO}, model 3: base model + maxOXPHOS_{FAO}, model 4: base model + VO₂peak, model 5: base model + VO₂peak + maxOXPHOS_{CHO}, model 6: base model + VO₂peak + maxOXPHOS_{FAO}.

Table 2. Cardiorespiratory fitness and mitochondrial energetics in older adults with and without diabetes

Model	Diabetes Status	VO ₂ peak	$OXPHOS_{CHO}$	_{max} OXPHOS _{CHO}	$_{\rm max}{ m ETS}_{ m CHO}$	$\mathrm{OXPHOS}_{\mathrm{FAO}}$	$_{\rm max}{\rm OXPHOS}_{\rm FAO}$
Unadjusted	WOD	1532.10 ± 16.67	31.08 ± 0.45	60.63 ± 0.74	81.43 ± 0.97	12.94 ± 0.22	58.22 ± 0.84
	WD	1513.75 ± 36.19	$\textbf{28.10} \pm \textbf{0.97}^{\text{\#}}$	$55.11 \pm 1.61^{\#}$	73.80 ± 2.11 #	11.93 ± 0.47	$\textbf{53.31} \pm \textbf{1.78}^{\#}$
Madal 1	WOD	1486.68 ± 19.07	30.14 ± 0.91	59.02 ± 1.45	77.53 ± 1.90	12.58 ± 0.47	59.25 ± 1.64
Model 1	WD	$1386.69 \pm 25.66^*$	$27.88 \pm 1.11^{\#}$	$54.98 \pm 1.80^{\#}$	$71.25 \pm 2.37^{\#}$	$11.49 \pm 0.55^{\#}$	$54.12 \pm 1.93^{\#}$
M- 1-11 + DA	WOD	1487.30 ± 19.53	30.15 ± 0.91	58.65 ± 1.47	$\textbf{77.02} \pm \textbf{1.98}$	12.60 ± 0.50	59.21 ± 1.61
Model 1 + PA	WD	$1412.11 \pm 26.03^{\#}$	28.51 ± 1.11	55.89 ± 1.78	$77.83 \pm 2.44^{\#}$	11.70 ± 0.59	$54.29 \pm 1.92^{\#}$
Model 1 +	WOD	1492.37 ± 19.52	30.34 ± 0.94	59.50 ± 1.49	77.64 ± 1.95	12.67 ± 0.48	59.83 ± 1.67
ASAT	WD	$1376.07 \pm 26.56^*$	$27.83 \pm 1.15^{\#}$	$55.07 \pm 1.82^{\#}$	$70.92 \pm 2.45^{\#}$	$11.37 \pm 0.57^{\#}$	$53.85 \pm 1.98^{\#}$
Model 1 + VAT	WOD	1488.92 ± 19.56	30.16 ± 0.94	59.16 ± 1.49	77.33 ± 1.96	12.62 ± 0.49	59.57 ± 1.68
	WD	$1386.86 \pm 26.60^*$	28.04 ± 1.15	$55.46 \pm 1.81^{\#}$	$\textbf{71.29} \pm \textbf{2.45}^{\#}$	$11.50 \pm 0.57^{\#}$	$54.66 \pm 1.98^{\#}$
Model 1 + QFI	WOD	1486.37 ± 19.00	30.28 ± 0.93	59.38 ± 1.48	$\textbf{77.78} \pm \textbf{1.94}$	12.68 ± 0.48	59.74 ± 1.68
	WD	$1386.10 \pm 25.75^*$	$27.97 \pm 1.14^{\#}$	$55.33 \pm 1.81^{\#}$	$71.06 \pm 2.43^{\#}$	$11.37 \pm 0.57^{\#}$	$54.22 \pm 1.98^{\#}$


Mean \pm standard error with significance accepted at *p<0.001, #p<0.05 and represented with bold font. Model 1 is adjusted for age, race, gender, site/technician, BMI, and comorbidities. PA = physical activity, ASAT = abdominal subcutaneous adipose tissue, VAT = visceral adipose tissue, QFI = muscle quadricep fat infiltration, WOD = without diabetes, WD = with diabetes, OXPHOS_{CHO} = carbohydrate supported respiration, maxOXPHOS_{CHO} = carbohydrate supported maximal complex I+II stimulated respiration, maxOXPHOS_{FAO} = fatty acid oxidation (FAO) supported respiration, maxOXPHOS_{FAO} = fatty acid oxidation supported maximal complex I+II stimulated respiration.


Table 3: Multivariable linear regression analysis for the association of diabetes with 400m and 4m walk speed

	Without Diabetes	With Diabe	etes
Multivariable model	$Means \pm SE$	$\beta \pm SE$	P
400m walk speed (m/sec)			
Base Model: adjusted for gender, age and race	1.06 ± 0.01	-0.05 ± 0.01	0.00
Model 2: base model plus maxOXPHOS _{CHO}	1.06 ± 0.01	-0.04 ± 0.02	0.02
Model 3: base model plus maxOXPHOS _{FAO}	1.06 ± 0.01	-0.04 ± 0.02	0.02
Model 4: base model plus VO ₂ peak	1.07 ± 0.01	-0.04 ± 0.01	0.01
Model 5: base model plus VO ₂ peak and maxOXPHOS _{CHO}	0.07 ± 0.01	-0.03 ± 0.02	0.07
Model 6: base model plus VO ₂ peak and maxOXPHOS _{FAC}	1.07 ± 0.01	-0.02 ± 0.02	0.20
Fully adjusted: model 5 plus BMI and comorbidities	1.06 ± 0.01	0.003 ± 0.01	0.87
Fully adjusted: model 6 plus BMI and comorbidities	1.06 ± 0.01	-0.005 ± 0.02	0.78
4m walk speed (m/sec)			
Base Model: adjusted for gender, age, and race	1.05 ± 0.01	-0.04 ± 0.02	0.01
Model 2: base model plus maxOXPHOS _{CHO}	1.04 ± 0.01	-0.03 ± 0.02	0.12
Model 3: base model plus maxOXPHOS _{FAO}	1.05 ± 0.01	-0.01 ± 0.02	0.51
Model 4: base model plus VO ₂ peak	1.05 ± 0.01	-0.04 ± 0.02	0.04
Model 5: base model plus VO ₂ peak and maxOXPHOS _{CHO}	0.01 ± 0.01	-0.02 ± 0.02	0.27
Model 6: base model plus VO ₂ peak and maxOXPHOS _{FAC}	1.05 ± 0.01	0.00 ± 0.02	0.99
Fully adjusted: model 5 plus BMI and comorbidities	1.05 ± 0.01	0.003 ± 0.02	0.84
Fully adjusted: model 6 plus BMI and comorbidities	1.05 ± 0.01	0.01 ± 0.02	0.50

Without diabetes, mean \pm standard error. With diabetes, β estimate \pm standard error with significance accepted at ***p<0.05**. maxOXPHOS_{CHO} = carbohydrate supported maximal complex I+II stimulated respiration, maxOXPHOS_{FAO} = fatty acid oxidation supported maximal complex I+II stimulated respiration. Models including maxOXPHOS_{CHO} and maxOXPHOS_{FAO} are adjusted for technician, and models with VO₂peak are adjusted for site.

Graphical Abstract





Functional Tests

Without Diabetes
N=717 400m walk speed
N=717 4m walk speed

With Diabetes
N=159 400m walk speed
N=159 4m walk speed

Mitochondrial Energetics

Without Diabetes N=663 ATPmax

N=614 OXPHOS_{CHO} N=612 maxOXPHOS_{CHO} N=503 maxETS

N=446 OXPHOS_{FAO} N=445 maxOXPHOS_{FAO}

With Diabetes

N=147 ATPmax N=130 OXPHOS_{CHO} N=130 maxOXPHOS_{CHO} N=106 maxETS N=100 OXPHOS_{FAO} N=99 maxOXPHOS_{FAO}

Cardiorespiratory Fitness

Without Diabetes
N=674 have data for VO₂peak

With Diabetes
N=143 have data for VO₂peak

Physical Activity

Without Diabetes
N=614 Total daily steps
N=556 Time spent sedentary
N=667 Time spent in light Physical activity
N=667 Time spent in moderate to vigorous physical activity

With Diabetes
N=137 Total daily steps
N=127 Time spent sedentary
N=153 Time spent in light Physical activity
N=153 Time spent in moderate to vigorous physical activity

Body Composition

Without Diabetes
N=681 Quadricep muscle fat
infiltration
N=683 Adipose tissue depots

With Diabetes
N=149 Quadricep muscle fat infiltration
N=149 Adipose Tissue depots

Supplemental Figure 1. SOMMA cohort sample size for analysis of muscle function, mitochondrial energetics, CRF, PA and body composition. Participants missing data for ex-vivo mitochondrial energetics is due exclusions samples passing quality control. Missing ATPmax measures were due to safety reasons or exclusion due to technical conditions during testing.

Supplemental Table 1. Association of hypoglycemic drugs and metformin with cardiorespiratory fitness and mitochondrial energetics

	All hypoglycemic agents		Metformin	
	β estimate	p-value	β estimate	p-value
VO ₂ peak	-82.27 ± 62.24	0.19	-13.08 ± 55.47	0.81
ATPmax	$\textbf{-0.05} \pm \textbf{0.03}$	0.05	-0.06 ± 0.02	0.01*
$OXPHOS_{CHO}$	-1.03 ± 2.01	0.61	-0.71 ± 1.81	0.70
${\rm maxOXPHOS_{CHO}}$	-3.52 ± 3.20	0.27	-3.11 ± 2.89	0.28
$maxETS_{CHO}$	-2.95 ± 4.45	0.51	-4.07 ± 4.04	0.32
$OXPHOS_{FAO}$	-1.35 ± 1.06	0.21	-0.68 ± 1.00	0.50
maxOXPHOS _{FAO}	-2.57 ± 3.69	0.49	-5.30 ± 3.43	0.13

 β estimate \pm standard error with significance accepted at **p<0.05**. Data adjusted for age, race, and site/technician. ATPmax = maximal adenosine triphosphate production, OXPHOS_{CHO} = carbohydrate supported respiration, maxOXPHOS_{CHO} = carbohydrate supported maximal electron transport system, OXPHOS_{FAO} = fatty acid oxidation (FAO) supported respiration, maxOXPHOS_{FAO} = fatty acid oxidation supported maximal complex I+II stimulated respiration.